Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920281 | 0.83 | SLC22A6 (0.33) | LTA4HSLC22A6 | |
| SCHEMBL15381953 | 0.74 | TP53 (0.33) | TP53 | |
| SCHEMBL4830064 | 0.74 | PIK3CD (0.35) | — | |
| SCHEMBL13656056 | 0.73 | THRB (0.42) | LTA4H | |
| SCHEMBL7639998 | 0.73 | LMNA (0.42) | LTA4HTP53SLC22A6 | |
| SCHEMBL584136 | 0.73 | LMNA (0.42) | LTA4HTP53SLC22A6 | |
| SCHEMBL1010259 | 0.73 | SLC22A6 (0.36) | LTA4HTP53SLC22A6 | |
| SCHEMBL8076303 | 0.72 | TP53 (0.50) | TP53 | |
| SCHEMBL8076301 | 0.72 | TP53 (0.50) | TP53 | |
| SCHEMBL28370787 | 0.71 | LTA4H (0.35) | LTA4HTP53SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9695119-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695119-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8580859-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2326619-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | Bioxiness Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010014943-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | LTA4H 2320/4885TP53 2757/4885SLC22A6 4665/4885 |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | LTA4H 2320/4885TP53 2757/4885SLC22A6 4665/4885 |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | LTA4H 2320/4885TP53 2757/4885SLC22A6 4665/4885 |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | LTA4H 2320/4885TP53 2757/4885SLC22A6 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.